Carl Dambkowski insider trades: Apogee Therapeutics (APGE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Carl reports to the SEC
Open-market buys and sales
28 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | APGE | ↓ Sell | 5,500 | $134.17 | $738K | Direct | Aug 7, 2026 (2d) |
| Jun 22, 2026 | APGE | ↓ Sell | 26,400 | $132.60 | $3.5M | Direct | Jun 24, 2026 (2d) |
| Jun 12, 2026 | ORKA | ↓ Sell | 35,000 | $70.13 | $2.5M | Direct | Jun 12, 2026 (0d) |
| May 21, 2026 | ORKA | ↓ Sell | 105,000 | $58.97 | $6.2M | Direct | May 22, 2026 (1d) |
| May 6, 2026 | APGE | ↓ Sell | 5,500 | $84.14 | $463K | Direct | May 8, 2026 (2d) |
| Apr 1, 2026 | APGE | ↓ Sell | 5,500 | $84.84 | $467K | Direct | Apr 3, 2026 (2d) |
| Mar 4, 2026 | APGE | ↓ Sell | 5,500 | $71.06 | $391K | Direct | Mar 6, 2026 (2d) |
| Feb 4, 2026 | APGE | ↓ Sell | 5,500 | $65.79 | $362K | Direct | Feb 4, 2026 (0d) |
| Jan 7, 2026 | APGE | ↓ Sell | 18,700 | $77.84 | $1.5M | Direct | Jan 9, 2026 (2d) |
| Dec 4, 2025 | APGE | ↓ Sell | 10,900 | $75.00 | $818K | Direct | Dec 5, 2025 (1d) |
| Nov 5, 2025 | APGE | ↓ Sell | 10,785 | $55.07 | $594K | Direct | Nov 7, 2025 (2d) |
| Oct 1, 2025 | APGE | ↓ Sell | 5,110 | $39.80 | $203K | Direct | Oct 3, 2025 (2d) |
| Sep 3, 2025 | APGE | ↓ Sell | 2,725 | $37.87 | $103K | Direct | Sep 5, 2025 (2d) |
| Aug 6, 2025 | APGE | ↓ Sell | 2,725 | $37.78 | $103K | Direct | Aug 8, 2025 (2d) |
| Jul 2, 2025 | APGE | ↓ Sell | 10,090 | $45.09 | $455K | Direct | Jul 3, 2025 (1d) |
| Jun 4, 2025 | APGE | ↓ Sell | 2,725 | $36.96 | $101K | Direct | Jun 6, 2025 (2d) |
| May 7, 2025 | APGE | ↓ Sell | 2,725 | $35.75 | $97K | Direct | May 9, 2025 (2d) |
| Apr 2, 2025 | APGE | ↓ Sell | 3,860 | $36.22 | $140K | Direct | Apr 4, 2025 (2d) |
| Mar 5, 2025 | APGE | ↓ Sell | 1,590 | $30.48 | $48K | Direct | Mar 7, 2025 (2d) |
| Feb 5, 2025 | APGE | ↓ Sell | 3,520 | $40.69 | $143K | Direct | Feb 7, 2025 (2d) |
| Jan 2, 2025 | APGE | ↓ Sell | 4,085 | $46.94 | $192K | Direct | Jan 3, 2025 (1d) |
| Dec 11, 2024 | APGE | ↓ Sell | 4,540 | $48.76 | $221K | Direct | Dec 13, 2024 (2d) |
| Dec 4, 2024 | APGE | ↓ Sell | 6,665 | $46.07 | $307K | Direct | Dec 6, 2024 (2d) |
| Nov 6, 2024 | APGE | ↓ Sell | 6,665 | $59.12 | $394K | Direct | Nov 8, 2024 (2d) |
| Oct 2, 2024 | APGE | ↓ Sell | 6,665 | $56.26 | $375K | Direct | Oct 4, 2024 (2d) |
| Sep 4, 2024 | APGE | ↓ Sell | 6,665 | $47.56 | $317K | Direct | Sep 6, 2024 (2d) |
| Aug 7, 2024 | APGE | ↓ Sell | 7,335 | $40.67 | $298K | Direct | Aug 9, 2024 (2d) |
| Jul 3, 2024 | APGE | ↓ Sell | 5,995 | $37.60 | $225K | Direct | Jul 5, 2024 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other APGE insiders
Open-market trades in the last 12 months
About Carl Dambkowski's insider trades
Carl Dambkowski is Chief Medical Officer at Apogee Therapeutics (APGE). Since Jul 3, 2024, Carl has reported no open-market purchases and 28 sales worth $21.2M on SEC Form 4. In the last 12 months: 10 sales ($16.8M).
Their filings also include option exercises (13 filings), grants and awards (5 filings), shares returned to the company (1 filing), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every APGE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.